The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases.
10.1016/j.apsb.2016.02.004
- Author:
Qingjie CHEN
1
,
2
;
Xiaofeng GUAN
3
;
Xiaocong ZUO
1
;
Jianglin WANG
3
;
Wenjun YIN
3
Author Information
1. Clinical Pharmacy and Pharmacology Research Institute, The Third Xiangya Hospital of Central South University, Changsha 410013, China
2. School of Pharmaceutical Sciences, Central South University, Changsha 410083, China.
3. Clinical Pharmacy and Pharmacology Research Institute, The Third Xiangya Hospital of Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- Keywords:
Acute kidney injury;
Antineutrophil cytoplasmic autoantibody-associated vasculitis;
Chronic kidney disease;
Clear cell renal cell carcinoma;
Diabetic nephropathy;
High mobility group box 1;
Inflammation;
Nephritis
- From:
Acta Pharmaceutica Sinica B
2016;6(3):183-188
- CountryChina
- Language:English
-
Abstract:
High mobility group box 1 (HMGB1) is a nuclear protein that can bind to DNA and act as a co-factor for gene transcription. When released into extracellular fluid, it plays a proinflammatory role by acting as a damage-associated molecular pattern molecule (DAMP) (also known as an alarmin) to initiate innate immune responses by activating multiple cell surface receptors such as the receptor for advanced glycation end-products (RAGE) and toll-like receptors (TLRs), TLR2, TLR4 or TLR9. This proinflammatory role is now considered to be important in the pathogenesis of a wide range of kidney diseases whether they result from hemodynamic changes, renal tubular epithelial cell apoptosis, kidney tissue fibrosis or inflammation. This review summarizes our current understanding of the role of HMGB1 in kidney diseases and how the HMGB1-mediated signaling pathway may constitute a new strategy for the treatment of kidney diseases.
